{
    "clinical_study": {
        "@rank": "24867", 
        "acronym": "SARMETA", 
        "arm_group": {
            "arm_group_label": "Dose escalation", 
            "arm_group_type": "Experimental", 
            "description": "SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose is 260mg/m2."
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      In the dose escalation: to determine the maximum tolerated dose (MTD) of SAR125844.\n\n      In the expansion cohort: to evaluate the preliminary anti-tumoral effect of SAR125844.\n\n      Secondary Objectives:\n\n      To characterize and confirm the global safety profile of SAR125844 including cumulative\n      toxicities.\n\n      To assess preliminary antitumor activity of SAR125844. To explore the pharmacodynamic\n      effects (PDy) of SAR125844. To evaluate the pharmacokinetic profile of SAR125844. To explore\n      the relationship of MET gene amplification status with anti-tumor effects.\n\n      To evaluate other pharmacodynamic biomarkers."
        }, 
        "brief_title": "Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasm Malignant", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "For both cohorts, escalation and expansion, the duration of the study for one patient will\n      include a period for inclusion of up to 3 weeks and a 4-week treatment cycle(s).The patient\n      may continue treatment until disease progression, unacceptable toxicity or willingness to\n      stop, followed by a minimum of 30-days follow-up.\n\n      If a patient treated in dose escalation part or in an expansion cohort, continues to benefit\n      from the treatment at the time of Clinical Study Report, the patient can continue study\n      treatment for a maximum of 1 year and will continue to undergo all assessments as per the\n      study flowchart. Such patients will be followed at least until 30 days after the last IMP\n      administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with solid tumor for which no standard therapy is available.\n\n          -  At the recommended dose (expansion cohort): only patients with measurable disease and\n             MET gene amplification.\n\n        Exclusion criteria:\n\n          -  Patient less than 20 years old.\n\n          -  ECOG performance status > 2.\n\n          -  Poor bone marrow reserve as defined by absolute neutrophils count < 1.5 x 109/L or\n             platelets < 100 x 109/L.\n\n          -  Poor organ function as defined by one of the following:\n\n          -  Total bilirubin > 1.5 x ULN\n\n          -  AST, ALT, alkaline phosphatase >2.5 x ULN  or > 5 x ULN in case of documented liver\n             metastasis\n\n          -  Serum creatinine > 1.5 x ULN,  or serum  creatinine between 1.0 and 1.5 x UNL\n             associated with calculated creatinine clearance < 60 mL/min\n\n          -  Proteinuria > 500mg/24h\n\n          -  Pregnant or breast-feeding women. Sexually active (males and females) who do not\n             agree to use medically acceptable methods of contraception during the course of the\n             study and for 3 months following discontinuation of study drug. Female patients of\n             childbearing potential must have a negative pregnancy test at screening.\n\n          -  Known or symptomatic brain metastasis (other than totally resected or previously\n             pre-irradiated and no progressive/relapsing) or lepto-meningeal carcinomatosis.\n\n          -  No resolution of any specific toxicities (excluding alopecia) related to any prior\n             anti- cancer -therapy to grade \u2264 1 according to the NCI CTCAE v.4.03.\n\n          -  Wash out period of less than 3 weeks from previous antitumor therapy or any\n             investigational treatment, (and less than 6 weeks in case of prior nitrozo-urea and\n             or mitomycin C treatment).\n\n          -  Any surgery with major risk of bleeding performed less than 10 days prior to study\n             treatment administration.\n\n          -  Any other severe underlying medical conditions, which could impair the ability to\n             participate in the study.\n\n          -  Patients treated with potent CYP3A inhibitor.\n\n          -  Patients treated with CYP3A inducers.\n\n          -  Known hypersensitivity or any adverse event related to the study drug excipient\n             (Captisol\u00ae).\n\n          -  Prior treatment with any MET inhibitor compound (selective or not).\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657214", 
            "org_study_id": "TED12337", 
            "secondary_id": "U1111-1126-7527"
        }, 
        "intervention": {
            "arm_group_label": "Dose escalation", 
            "description": "Pharmaceutical form:Concentrate for solution\nRoute of administration: intravenous", 
            "intervention_name": "SAR125844", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sunto-Gun", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Investigational Site Number 410001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Investigational Site Number 410002"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I, Dose Escalation Study of Safety, Pharmacokinetic and Pharmaco-Dynamic of SAR125844 Administered Weekly as Intravenous Infusion in Asian Adult Patients With Advanced Malignant Solid Tumors", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Dose escalation to determine the maximum tolerated dose (MTD) of SAR125844", 
                "safety_issue": "Yes", 
                "time_frame": "At day 28 of Cycle 1 of each treated patient, DLT is assessed"
            }, 
            {
                "measure": "Expansion cohort to evaluate the preliminary anti-tumoral effect of SAR125844", 
                "safety_issue": "No", 
                "time_frame": "Anticancer activity is assessed at day 28 and then every 8 weeks thereafter up to an expected maximum of 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657214"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with treatment emergent events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to a maximum of 2 years"
            }, 
            {
                "measure": "Assessment of PK parameter Cmax", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 2 years"
            }, 
            {
                "measure": "Assessment of PK parameter AUCs", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 2 years"
            }, 
            {
                "measure": "Assessment of PK parameter CL", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 2 years"
            }, 
            {
                "measure": "Assessment of PD parameter ShedMET", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 2 years"
            }, 
            {
                "measure": "Assessment of PD parameter HGF", 
                "safety_issue": "No", 
                "time_frame": "Up to a maximum of 2 years"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}